The results of the first collection of proprietary Chinese medicines were announced: the biggest drop was 82.63%!

Time flies, and the last month of 2021 will end today
.
The medical insurance catalog is undoubtedly the most concerned medical policy at the end of each year
.
On December 3, the results of the adjustment of the medical insurance catalog were officially released: a total of 74 drugs were added to the catalog and 11 drugs were removed from the catalog
.
Judging from the negotiation situation, the negotiation of 67 kinds of exclusive drugs out of the catalogue was successful, with an average price reduction of 61.
71%
.
2021 is the fourth consecutive year since the establishment of the National Medical Insurance Administration to carry out the adjustment of the national medical insurance drug catalogue
.
The performance of domestically produced PD-1 is as usual this year, except for the two new indications of Hengrui PD-1 that have not been covered by medical insurance, the others have been successfully included
.
In addition, 7 kinds of orphan drugs for rare diseases have been included this year, but the prices are still confidential
.
Because the market for rare disease drugs is relatively small, it is difficult to rapidly increase the volume through price cuts like other drugs
.
The substantial price cut in the rare disease medical insurance negotiations will indeed benefit patients, but the profit return may be limited by the medical insurance price
.
At present, domestic rare disease drugs are mainly imported.
Imported rare pathogen research companies are expected to have already recovered the research and development costs in the European and American markets before they are willing to reduce their prices to enter medical insurance
.
Under this circumstance, it may be difficult to advance the research and development of new drugs for domestic rare disease drugs
.
This month, the results of the first centralized procurement of Chinese patent medicines (Hubei 19 Provincial Alliance) were released
.
Through competition, a total of 97 companies and 111 products were selected.
The average price drop of the proposed selection was 42.
27%, and the largest drop was 82.
63%
.
Chinese patent medicine is different from chemical medicine, which is difficult to measure.
It has always been a difficult point for centralized procurement and expansion
.
In addition to Hubei this year, the 6-province alliance of Guangdong has conducted centralized procurement of proprietary Chinese medicines, and it is now coming to an end
.
The rules of the two major alliances are different.
Several provinces overlap, and some centralized procurement products also overlap.
Some problems have yet to be resolved
.
As a local attempt for centralized procurement of Chinese patent medicines, it may have a profound impact on the pharmaceutical market in the future, and the Chinese medicine industry may reshuffle.

.
Other highlights of this month: Henan pilot retail pharmacies have been included in the scope of centralized procurement, medical institutions have begun to allocate insulin purchases, Shandong's renewed bids have dropped by 97%, and 32 cities have launched DRG/DIP payment methods.
.
.